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Expectations, positive or negative, are modu-
lating factors influencing behavior. They are
also thought to underlie placebo effects, im-
pacting perceptions and biological processes.
Using healthy human subjects, we examined
the role of the nucleus accumbens (NAC), a
region centrally involved in the encoding of
reward expectation, in the formation of placebo
responses. Employing functional molecular im-
aging, activation of NAC dopamine (DA) release
was observed during placebo administration
and related to its anticipated effects, percep-
tion-anticipationmismatches, and placebo effect
development. In additional functional MRI stud-
ies, the expectation of monetary gain increased
NAC synaptic activity in a manner proportional
to placebo-induced DA release, anticipated ef-
fects, perception-anticipation differentials, and
actual placebo effects. Individual variations in
NAC response to reward expectation accounted
for 28% of the variance in the formation of
placebo analgesia.
INTRODUCTION
A common phenomenon across a variety of human expe-
riences is the extent to which our expectations about an
event, whether positive or negative, direct behavior to en-
sure future reward acquisition or to avoid potential harm. It
is thought that these effects are mediated by specific
neuronal circuits linking cognitive, emotional, and motor
responses traditionally studied in the context of the pursuit
of natural (e.g., food), monetary, and drug rewards (Kali-
vas et al., 1999; Mogenson and Yang, 1991; Tom et al.,
2007). However, individual expectancies also shape the
actual perception and experience of events, not just
motivated behavior. For example, the anticipation that
a noxious challenge would be of higher or lower intensityhas been shown to increase and diminish subjective re-
port, as well as the brain regional responses to otherwise
identical stimuli. The neural effects have consistently in-
volved the anterior cingulate and posterior insula,
areas implicated in the perception and regulation of pain
signals (Keltner et al., 2006; Koyama et al., 2005; Sawa-
moto et al., 2000). Environmental challenges threatening
homeostasis and positive expectations capable of reduc-
ing the bodily response are therefore interacting with
each other conferring vulnerability and resiliency, respec-
tively. These effects are thought to be the basis for the
formation of placebo effects and point to individual ex-
pectancies as important modifiers of biological processes
in both health and disease. However, the processes by
which anticipation translates into measurable biological
responses are unknown, this being a question of profound
relevance to medicine and human biology. Placebo ef-
fects are an important confound in medical trials (Hrob-
jartsson and Gotzsche, 2001), while at the same time
they represent a resiliency mechanism favoring homeo-
stasis. The larger the anticipated benefit from a drug or
a procedure, typically the greater is the actual health im-
provement observed (de Craen et al., 2000; Moseley
et al., 2002).
In nonhuman primates and rodents, brainstem ventral
tegmental area (VTA) dopaminergic cells projecting to
the nucleus accumbens (NAC) of the ventral basal ganglia
respond to both themagnitude of anticipated rewards and
deviations from the predicted outcomes, serving as an
adaptive system modulating behavioral responses
(Schultz, 2006; Setlow et al., 2003; Tobler et al., 2005).
Based on this information and if the placebo effect is con-
sidered a form of reward anticipation response, it has
been hypothesized that the activity of mesolimbic dopa-
mine (DA) cells during reward anticipation and their capac-
ity to adapt to environmental information underlies pla-
cebo responding in humans (Fields, 2004; Irizarry and
Licinio, 2005). DA activation in the NAC has been detected
with positron emission tomography (PET) during receipt of
a placebo in patients diagnosed with Parkinson’s disease
in a manner proportional to the anticipated improvement
in motor control (de la Fuente-Fernandez et al., 2002).
However, no relationship was found between NAC DANeuron 55, 325–336, July 19, 2007 ª2007 Elsevier Inc. 325
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These were, in fact, ascribed to DA activity in nigrostriatal
projection regions (caudate and putamen) (de la Fuente-
Fernandez et al., 2001). Along similar lines, Petrovic and
collaborators, using functional magnetic resonance imag-
ing (fMRI) (Petrovic et al., 2005), described a correlation
between ratings of negative affect improvement during
preconditioning with a benzodiazepine and ventral basal
ganglia synaptic activity after receipt of a placebo. These
reports seem to confirm an involvement of NAC DA and
synaptic activity in the expectations created by the intro-
duction of a placebo, or in the case of the latter work,
in conditioned responses. Nevertheless, how these ef-
fects are related to actual placebo effects and whether
individual differences in NAC function underlie individual
variations in the biological effects of placebos remains
unknown. Alternatively, placebo-associated changes in
NAC and mesolimbic DA function could simply form part
of an epiphenomenon related to the organism response
to a salient stimulus (i.e., the placebo) without physio-
logical relevance other than directing attention to that
stimulus.
These questions were examined in a sample of healthy
humans with a combination of studies employing PET and
[11C]raclopride and fMRI. The studies were described as
a randomized control trial of a novel analgesic agent
and that either a placebo or an active agent could be
administered. In that manner, we hoped to elicit a full
range of expectations and placebo effects that would
allow the study of interindividual differences in these
phenomena. The placebo consisted of 1 ml of isotonic sa-
line delivered intravenously every 4 min. The 20 min pain
expectation periods were followed by an actual pain
challenge that was maintained for 20 min. Molecular
imaging was employed to measure placebo-induced DA
release during the pain expectation state. This would be
reflected by reductions in the in vivo receptor availability
(binding potential, BP) during pain anticipation scans
when the placebo was administered. To determine
whether individual differences in placebo effects are re-
lated to variations in the biological response to reward an-
ticipation, subjects also underwent an fMRI study using
the Monetary Incentive Delay (MID) task. This task acti-
vates NAC synaptic activity during the anticipation of a re-
ward (Knutson et al., 2004). Interindividual variations in
NAC DA responses to placebo administration were then
compared with the synaptic activity of the same region
during anticipation of a monetary reward. Both these
measures were then examined as a function of the antic-
ipated analgesic effects of the placebo, deviations from
those expectations, and the magnitude of placebo anal-
gesic effects in pain challenges. It was hypothesized
that in healthy subjects, in the absence of underlying pa-
thology or previous conditioning, interindividual variations
in placebo-induced NAC DA activity and in the synaptic
activity of this region during reward anticipation would
be related to the variability in placebo effects obtained
in the studies.326 Neuron 55, 325–336, July 19, 2007 ª2007 Elsevier Inc.RESULTS
Dopaminergic Mechanisms in the Formation
of Placebo Effects
Fourteen of the volunteers (sevenmale, seven female) par-
ticipated in the functional molecular PET and [11C]raclopr-
ide studies. This is a DA D2 receptor radioligand that also
labels D3 receptors in the NAC (Seeman et al., 2006). Each
subject was studied during conditions of expectation of
a painful challenge with and without the administration of
a placebo with potential analgesic properties. Anticipated
analgesia ratings averaged 37 ± 26 (mean ± 1 SD) (range
0–95), using a 0–100 visual analog scale (VAS = 0 not ex-
pected to be effective, 100 complete effectiveness). These
studies were followed by actual pain challenges, with and
without placebo administration, lasting for 20 min each
(Figure 1A). Subjective ratings of placebo analgesia ac-
quired at that time were rated at 35 ± 30 (range 0–80,
with 0 = completely ineffective and 100 = completely
effective). The mismatch between anticipated and per-
ceived placebo effects was also computed (analgesia
perceived minus anticipated, 2 ± 31, range 60 to 60).
Prior to the induction of pain, placebo effects during
pain expectation were determined using the Positive and
Negative Affectivity Scale (PANAS; Watson et al., 1988)
affect ratings. Placebo administration was associated
with reductions in PANAS negative affect ratings (2.3 ±
2.4 without placebo to 1.5 ± 2.7 with placebo, one-tail
paired t test, t = 2.8, p < 0.01). Fear ratings were also
reduced (2.2 ± 2.2 to 1.0 ± 2.0, t = 4.5, p = 0.001), while
positive affect ratings showed a trend toward increases
(6.9 ± 6.1 without placebo to 9.5 ± 9.2 with placebo, t =
1.6, p < 0.08).
In the pain challenges that followed, placebo-induced
analgesic effects were determined by contrasting studies
with and without the administration of the placebo using
the change in pain intensity ratings acquired every 15 s
for the 20 min duration of the challenges (df = 13, paired
one-tail t tests). For the entire sample, the average pain
intensity ratings were 33 ± 14 without and 27 ± 12 with
placebo (average within subject reduction 6 ± 10 VAS
units, t = 1.8, p = 0.04) (Figure 1C).
We also examined whether placebo effects on pain rat-
ings could be explained by the order in which the studies
were conducted, as placebo administrations always fol-
lowed pain challenges to provide a frame of reference to
the subjects. For this purpose, a separate sample of 18
healthy males 20–30 years of age was studied twice with
the same experimental protocol, except that no scanning
was performed and subjects did not receive the placebo.
Average VAS pain intensity ratings over 20 min were
32 ± 13 for studies conducted first in order, and 31 ± 13
for those second in order (paired one-tail t test, t = 0.6,
p = 0.3).
Significant differences for the change in pain ratings be-
tween placebo and no intervention group were obtained,
confirming the development of a placebo analgesia
that was not confounded by order effects (two-sample,
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Dopamine, Reward, and the Placebo EffectFigure 1. Activation of Dopamine D2/D3 Neurotransmission During Placebo Administration
(A) Experimental design. Each subject received two scans with the DA D2/D3 radiotracer [11C]raclopride. Pain expectation conditions took place in
the presence and absence of placebo with expectation that it was an analgesic agent. These were followed by pain challenges of moderate intensity
with and without placebo.
(B) Magnitude of significant regional BP changes (in vivo measure of endogenous neurotransmitter release) during placebo administration in [11C]-
raclopride scans (mean ± SEM). GV, global brain BP value; L NAC, left nucleus accumbens; R NAC, right nucleus accumbens.
(C) VAS ratings of pain intensity over the 20 min pain challenge, acquired every 15 s, before and after placebo administration (mean ± SEM) in all
subjects and in high responders to placebo administration.
(D) VAS ratings of pain intensity over the 20min pain challenge, repeated twicewithout placebo administration (‘‘natural history’’ group) (mean ± SEM).one-tail t test, t = 2.1, p = 0.02). Pain ratings over time dur-
ing the no intervention studies are shown in Figure 1D.
Analgesic effects were also examined as a function of
time (divided into acute, tonic, and sustained pain phases)
to determine whether one or more parts of the 20 min pain
challenge were more susceptible to placebo analgesic ef-
fects and for comparability with pain models of shorter du-
ration (Grevert and Goldstein, 1977; Amanzio and Bene-
detti, 1999). For the initial acute pain intensity ratings
(peak rating after a 0.15 ml bolus of 5% hypertonic saline
administered over 15 s) pain ratings were 60 ± 23 VAS in-
tensity units before and 56 ± 18 after placebo (t = 0.9, p =
0.2). Ratings over the first 10 min of the challenge (tonic
pain) were 33 ± 16 (pain) and 27 ± 10 (pain + placebo)
(t = 1.6, p = 0.06). During the last 10 min of the challenge
(sustained pain phase), these were 33 ± 15 (pain) and26 ± 14 (pain + placebo) (t = 2.4, p = 0.02). Placebo effects
then appeared more prominent for tonic or more sus-
tained phases of pain, as opposed to brief, phasic pain
(Figure 1C).
The anticipation of analgesia was significantly and pos-
itively correlated with the average reduction in pain ratings
during pain + placebo studies (r = 0.48, p < 0.05), as was
the difference between perceived and anticipated analge-
sia (r = 0.54, p < 0.05).
For analyses of imaging data, individuals were grouped
into high and low placebo analgesia responders using the
median value of the average change in pain intensity rat-
ings over the 20 min challenges. Placebo responders
above the median (high responders) showed average re-
ductions in pain intensity of 11 ± 7 VAS units (Figure 1C),
while a 0.2 ± 10 VAS intensity unit reduction wasNeuron 55, 325–336, July 19, 2007 ª2007 Elsevier Inc. 327
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Analgesic Effects and Placebo-Induced DA Release
(A) Significant correlations between expected levels of analgesia prior to placebo administration and placebo-induced DA release in the right and left
NAC.
(B) Significant correlations between the difference between the experienced and expected placebo effect and placebo-induced DA release in the right
and left NAC.recorded in placebo responders below the median (low
placebo responders) (n = 7 in each group).
In the DA receptor quantification scans acquired during
pain expectation, volumes of interest placed in the NAC
bilaterally demonstrated placebo-induced activation of
DA D2/D3 neurotransmission, evidenced by significant re-
ductions in BP. These averaged 11.0% in the left and
8.1% in the right NAC (left NAC BP, 1.3 ± 0.2 without
and 1.2 ± 0.3 with placebo, paired one-tail t test, t = 2.5,
p < 0.02; right NAC BP, 1.7 ± 0.3 without and 1.6 ± 0.4
with placebo, paired one-tail t test, t = 1.8, p = 0.05)
(Figure 1B). No significant sex differences in placebo-
induced DA release were obtained, nor correlations be-
tween DA release and estradiol or progesterone plasma
levels in females (p > 0.05). Progesterone levels were
uniformly low for this sample of women, who were studied
in the follicular phase of the menstrual cycle.
No significant correlations were obtained between the
placebo effect during pain expectation trials (the change
in PANAS negative, positive, or fear scores with placebo)
and right or left NAC DA activity (p > 0.05). However, when
subjects were grouped into high and low placebo re-
sponders using a median split of the placebo-induced
change in positive affect during pain expectation, signifi-
cant differences in DA activation were obtained in the
left NAC (high responders 20 ± 16%, low responders 2 ±
11% change in BP, t = 2.3, p = 0.02). Effects in the same
direction were obtained for the right NAC, but did not
reach statistical significance (high responders 9 ± 14%,
low responders 2 ± 6% change in BP, t = 1.2, p = 0.1).
No significant differences in placebo-induced NAC DA re-
lease were obtained for subject groupings using placebo-
induced changes in PANAS negative affect or fear ratings
(p > 0.05).328 Neuron 55, 325–336, July 19, 2007 ª2007 Elsevier Inc.The magnitude of placebo-induced DA activation in the
NAC, bilaterally, was positively associated with the antic-
ipated effectiveness of the placebo as rated by the volun-
teers prior to its introduction (right, r = 0.69, p < 0.005; left,
r = 0.67, p = 0.005) (Figure 2A). More relevant to the elici-
tation of placebo analgesic effects, similar relationships
were obtained between placebo-induced NAC DA acti-
vation and the mismatch between its perceived effective-
ness and the anticipated placebo analgesia (right, r = 0.46,
p < 0.05; left, r = 0.66, p < 0.005) (Figure 2B).
The high placebo analgesia group in the pain trials also
demonstrated significantly greater magnitudes of right
NACDA responses to placebo during the pain expectation
PET studies than low placebo analgesia responders (high
placebo analgesia group, 15 ± 13% reduction in DA D2/
D3 BP, low placebo analgesia, 0.4 ± 7%, unpaired one-
tail t test, t = 2.5, p < 0.02). However, no significant corre-
lations were obtained between these two variables (p >
0.05). No significant effects were obtained for the left
NAC in t tests or correlations (p > 0.05).
In the low placebo response group, four individuals
reported increases in pain intensity during placebo admin-
istration (hyperalgesia during placebo administration,
a possible nocebo effect) that reached statistical signifi-
cance (placebo hyperalgesia group 10.0 ± 2.3 increase
in average VAS intensity ratings, remainder of the sample
11.3 ± 10.9 reduction, unpaired t test, t = 5.7, p < 0.0001).
These subjects showed lower levels of placebo-induced
DA release compared to the remainder of the group in
the right NAC, with a mean in the direction of ‘‘deactiva-
tion’’ (change in BP, hyperalgesia/nocebo responders,
0.2 ± 6.3% increases in BP, remainder of the sample
5.9 ± 10.3% reductions in BP), albeit these differences
did not reach statistical significance with the small sample
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Dopamine, Reward, and the Placebo EffectFigure 3. Relationship between Reward Anticipation and Individual Differences in Placebo Effects
(A) Experimental design. TheMonetary Incentive Delay task (Knutson et al., 2001) was employed to activate brain regions involved in reward process-
ing. A cue representing a monetary value is followed by an anticipation phase and a neutral target requiring button press and presented for variable
intervals depending on the previously recorded reaction time of the subject to ensure at least 66% correct target presses.
(B) Percent change in the NAC fMRI BOLD signal from null ($0) to low ($0.20), intermediate ($1) and high ($5) monetary reward trials (mean ± SEM).
(C) Correlations between right NAC fMRI BOLD signal change from null ($0) to high ($5) reward trials and placebo-inducedNACDAD2/D3 activation of
DA neurotransmission during pain expectation.
(D) Interaction between reported and expected placebo effectiveness and right NAC responses to increasing monetary reward value (mean ± SEM).size of the nocebo group. Changes in left NAC DA D2/D3
receptor BP were similar for hyperalgesia/nocebo re-
sponders and other subjects, however (hyperalgesia/
nocebo group 6.8 ± 11.7%; others 8.0 ± 8.8%; decreases
in BP in both cases).
The results of the functional molecular imaging studies
indicate that ventral basal ganglia DA neurotransmission
is activated in response to the introduction of a placebo
in a manner proportional to its anticipated benefit. The im-
aging data were obtained in the absence of actual pain
(pain expectation periods), and therefore do not represent
a response motivated by varying experiences of pain at
the time, known to influence placebo responding (Zubieta
et al., 2006). They may then more closely relate to individ-
ual variations in NAC DA reactivity to salient cues, in this
case the placebo, of potential benefit to the subject. In
this regard, we show that the difference between subjec-
tively experienced and anticipated placebo effects was
related to the magnitude of NAC DA D2/D3 system activa-
tion during placebo administration. Furthermore, high pla-cebo analgesia responders in pain trials following the
imaging experiments were characterized by more pro-
nounced NAC DA activity during placebo administration
in the pain expectation periods that preceded them.
Individual Differences in the Formation of Placebo
Effects Reflect Variations in Nucleus Accumbens
Reward Processing
Thirty volunteers (23 male, 7 female) were available for ad-
ditional fMRI studies that involved using the MID task
(Knutson et al., 2001). In this task, subjects were pre-
sented with a visual stimulus representing null ($0.00),
low ($0.20), intermediate ($1.00), or high ($5.00) monetary
reward values. This was followed by an anticipatory state,
a neutral target, and the announcement that the expected
reward was received (Knutson et al., 2001). The protocol
and responses of the NAC to varying levels of anticipated
rewards are shown in Figure 3A.
Significant increases in blood-oxygenation level
dependent (BOLD) fMRI signal, reflecting brain neuronalNeuron 55, 325–336, July 19, 2007 ª2007 Elsevier Inc. 329
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the NAC, bilaterally, during the anticipation of monetary
rewards in a manner proportional to reward value, as pre-
viously reported (Knutson et al., 2001) (Figure 3B depicts
the average changes in right and left NAC BOLD signal).
We then testedwhether variations in NAC synaptic activity
levels during the anticipation of the larger monetary gain
($5.00), compared to the null condition ($0.00), were re-
lated to the formation of placebo effects.
In this sample, significant effects of placebo during pain
anticipation were obtained for PANAS negative (t = 1.9, p <
0.04) and fear (t = 2.4, p = 0.02), but not positive affect rat-
ings (t = 0.9, p = 0.2). Placebo analgesic effects during
pain trials were also significant across the entire group
(t = 1.7, p < 0.05).
A significant positive correlation was obtained between
right NAC BOLD fMRI activation during monetary reward
anticipation and the anticipated effectiveness of the pla-
cebo (r = 0.79, p < 0.001), similarly to the results obtained
with placebo-induced NAC DA release. Also as observed
for placebo-induced NAC DA release, the mismatch be-
tween perceived effectiveness and anticipated placebo
analgesic effects was positively correlated with NAC
synaptic activity during monetary reward anticipation (r =
0.56, p < 0.001).
The relationships between anticipated and subjectively
perceived effects of placebo administration and the NAC
BOLD response to rewardwere further explored by group-
ing subjects into those finding the placebo as more (n = 7),
equally (n = 16) or less effective (n = 7) than anticipated.
Right NAC responses to small ($0.20), medium ($1.00),
and large ($5.00) rewards were examined for these three
groups of subjects with two-way ANOVA (independent
variables, group and reward level; dependent variable,
rightNACBOLD responses).Group3 reward level interac-
tionswereobtained (F=2.95, p=0.02).Subjects that found
the placebo either more or equally effective than antici-
pated demonstrated parametrically increasing right NAC
responses to increasing levels of expected reward value.
Individuals that rated the placebo as less effective than an-
ticipated did not demonstrate parametrically increasing
NAC responses as a function of reward values (Figure 3D).
Positive correlations were also obtained between fMRI
BOLD activation during reward anticipation and the anal-
gesic effects of the placebo during pain trials (the differ-
ence between average pain intensity ratings over the 20
min) (r = 0.53, p = 0.02), accounting for 28% of the vari-
ance in the formation of placebo analgesia. Furthermore,
the magnitude of right NAC synaptic activity during the re-
ward anticipation task was positively correlated with pla-
cebo-induced DA activation in the right and left NAC in
the 14 volunteers who participated in both PET and fMRI
studies (right, r = 0.51, p < 0.04; left, r = 0.52, p < 0.04) (Fig-
ure 3C). No significant sex differences or correlations with
estradiol or progesterone were obtained for right NAC
BOLD activation (p > 0.05).
In view of previous data linking changes in positive af-
fect and NAC responses to monetary reward (Knutson330 Neuron 55, 325–336, July 19, 2007 ª2007 Elsevier Inc.et al., 2005), subjects were grouped into high and low pla-
cebo responders using the median value of the change in
PANAS positive affect score (during pain expectation).
Similar median splits were performed for pain intensity rat-
ings in pain trials before and after placebo administration.
High PANAS positive placebo responders during pain
expectation trials demonstrated significantly greater right
NAC activation during monetary reward anticipation than
low placebo responders (percent BOLD signal change
from null to $5.00 conditions, high PANAS positive affect
responders, 0.82 ± 0.45%, low PANAS responders
0.56 ± 0.38%, unpaired one-tail t test, df = 28, t = 1.7,
p < 0.05). However, no significant correlations were ob-
tained between the placebo-induced change in PANAS
positive or negative affect during pain expectation and
NAC activity during anticipation of reward (p > 0.05).
When subjects were grouped as high or low placebo re-
sponders using the analgesic effect of the placebo during
pain trials as the classifying factor, high placebo analgesia
responders also demonstrated greater right NAC re-
sponses during reward anticipation (percent BOLD signal
change from null to $5.00 conditions, high placebo anal-
gesia group 0.76 ± 0.45%, low analgesia group 0.48 ±
0.31%, unpaired one-tail t test, df = 28, t = 1.9, p < 0.05).
In the sample studied with fMRI, 8 subjects demon-
strated hyperalgesia during placebo administration (pos-
sible nocebo response): 11.4 ± 7.9 increase in average
intensity pain ratings; reminder of the sample, 12.5 ± 6.7
reduction in pain ratings. Right NAC BOLD signal during
monetary reward anticipation was significantly lower in
the hyperalgesia/nocebo group compared to the rest of
the subjects (hyperalgesia/nocebo group 0.4 ± 0.3% in-
crease in NAC BOLD signal; others, 0.8 ± 0.6% increase
in BOLD, unpaired one-tail t test, t = 2.0, p < 0.03).
DISCUSSION
The present report implicates NAC DA in placebo re-
sponses when there is anticipation of analgesia. We uti-
lized an experimental design similar to those of clinical
randomized controlled trials (no preconditioning or sub-
ject preselection, no deception, either an active or an inac-
tive drug could be administered), allowing for a full range
of expectations and placebo effects. This design was as-
sociated with relatively modest placebo effects across the
entire sample, but permits the assessment of individual
variations in this phenomenon. The introduction of a pla-
cebowas associated with the activation of DA neurotrans-
mission and D2/D3 receptors in a manner proportional to
the anticipated analgesic effects of the otherwise inert
agent, as well as with the difference between anticipated
and subjectively perceived effectiveness of the placebo.
The magnitude of placebo-induced DA responses, mea-
sured during expectation of pain, further predicted the
subsequent development of placebo-induced analgesia
in pain trials.
These findings point to individual variations in response
to positive expectations, in this case elicited by the
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anticipated and perceived outcomes as cognitive ele-
ments associated with placebo-induced activation of
NAC DA neurotransmission.
In additional studies, we examined whether individual
variations in the synaptic activity of the NAC during
a task involving the anticipation of a monetary reward
would be predictive of the level of placebo effects. Recent
data in animal models has shown that DA cells innervating
the NAC encode expected reward values, but also devia-
tions from the expected outcomes (Tobler et al., 2005).
While it has been postulated that these mechanisms
may underlie placebo effects, the data so far acquired
by various groups has not demonstrated that NAC func-
tion, whether measured as DA release or as synaptic ac-
tivity with fMRI, is related to the formation of observable
placebo effects. In an initial report, NAC DA release as
measured with PET and [11C]raclopride during placebo
administration in patients diagnosed with Parkinson’s dis-
ease was related to the expected improvement in motor
control but not to the observed changes in motor function
(de la Fuente-Fernandez et al., 2001, 2002). Subsequent
work using fMRI and a negative emotional challenge
showed that the subjective report of treatment efficacy
during preconditioning with a benzodiazepine anxiolytic
was correlated with NAC synaptic activity during adminis-
tration of a placebo, but no relationship between NAC ac-
tivity and placebo effects was found (Petrovic et al., 2005).
Here, subjects underwent an fMRI protocol involving
anticipation of a monetary reward. It was shown that indi-
viduals that activated NAC synaptic function to a greater
extent during monetary reward anticipation also showed
more profound placebo responses. These included
greater positive affect scores during pain expectation pe-
riods and greater levels of analgesia in pain trials. The NAC
BOLD response during monetary reward anticipation was
further correlated with placebo-induced DA activity,
showing that individual differences in the placebo re-
sponse could be attributed to differences in NAC function
at the levels of DA neurotransmission and synaptic activity
during reward expectation. In fact, NAC synaptic activa-
tion during anticipation of the (high) monetary reward ac-
counted for approximately one third of the variance in
the development of placebo-induced analgesia. In a man-
ner similar to the results obtained with NAC DA responses
to placebo, the activation of NAC synaptic activity during
reward expectation was significantly correlated to the dif-
ference between the anticipated and subjectively per-
ceived analgesic effects of the placebo. It should be noted
that the fMRI studies were conducted separately from the
pain expectation and pain studies and that the subjects
were not aware of any link between the two sets of exper-
iments. The results then reflect intrinsic differences in the
response of the NAC during reward anticipation, further
defining individual variations in placebo responding.
Individual differences in responses to reward expecta-
tion were further examined as a function of whether sub-
jects rated the placebo as more, equally, or less effectivethan initially anticipated. The group rating the placebo as
more effective or equally effective than anticipated also
activated the NAC in a manner proportional to the value
of expected monetary rewards. However, subjects per-
ceiving the placebo as less effective than anticipated did
not show parametric increases in NAC activity as a func-
tion of expected reward value. Variations in the processing
of expected rewards are therefore shown to reflect the
capacity of the individual to respond to placebo adminis-
tration.
The NAC is a central component of the brain reward
system, receiving dense DA projections from the ventral
tegmental area. NAC DA neurotransmission is thought to
respond to salient stimuli, traditionally studied in the con-
text of the pursuit of natural as well as drug rewards (Ber-
ridge and Robinson, 2003; Robinson and Berridge, 2000),
but also to noxious or nonrewarding salient stimuli, includ-
ing pain (Horvitz, 2000; Scott et al., 2006; Setlow et al.,
2003; Zink et al., 2003). Emerging data suggest, however,
that NAC DA mechanisms have a more basic role in the
encoding of reward expectancy and variations from ex-
pected outcomes, as opposed to a simple response to ac-
tual rewards (Berridge and Robinson, 2003; Schultz, 2006;
Tobler et al., 2005). Experimental data in human subjects
seems to support this view. NAC synaptic activity, as
measured with fMRI, has been shown to increase with
the expectation of a monetary reward, but less prominent
effects were observed when the reward was actually ob-
tained (Knutson et al., 2001). From the NAC, it is believed
that the incentive signal is transmitted to other loci, such
as the ventral pallidum, amygdala, medial thalamus, and
prefrontal cortex, areas of importance for the integration
and expression of motivated behaviors, the so-called
‘‘motive’’ or ‘‘motivation’’ network (Kalivas et al., 1999;
Mogenson and Yang, 1991). Notable in this context is
the fact that a number of these regions (prefrontal cortex,
anterior cingulate, nucleus accumbens, thalamus, and
insular cortex) have been shown to respond with synaptic
activation (Petrovic et al., 2002; Wager et al., 2004) and
the release of endogenous opioids (Zubieta et al., 2005)
during placebo administration and expectation of
analgesia.
In humans, the neural responses to expectancies,
gains, and losses have been studied in the context of
gambling theory, where the brain responses to potential
gains and losses are related to the initial expectations of
the individual. Framed in the context of prospect theory
(Kahneman and Tversky, 1979) and decision affect theory
(Mellers et al., 1997, 1999), potential gains are evaluated
depending on the risk for loss, leading to decisions that
disregard the actual gains or losses in monetary terms.
For example, the absence of gain is evaluated positively
if a loss was expected and negatively if a gain was the ini-
tial expectation, albeit the outcome was the same in either
case. Positive expectations, outcomes, and counterfac-
tual comparisons, the relationship between anticipated
and obtained outcomes, have been shown to linearly in-
crease the activity of the NAC in fMRI studies (BreiterNeuron 55, 325–336, July 19, 2007 ª2007 Elsevier Inc. 331
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Tom et al., 2007).
The data presented here demonstrate that placebo re-
sponding follows identical patterns, with anticipated pla-
cebo effects and the mismatch between anticipated and
perceived outcomes (counterfactual comparisons) being
linearly related to the activation of NACDA neurotransmis-
sion during placebo administration. Furthermore, the indi-
vidual neural responses to anticipated monetary rewards
tracked the subjects’ expectations of analgesia and devi-
ations from those predictions. This demonstrates that
placebo-induced neurochemical and psychophysical re-
sponses are an example of reward processing, and that
individual variations in placebo responding are associated
with differences in reward expectation processing. In
Knutson et al. (2005), it was further observed that NAC ac-
tivity during reward expectation was correlated with self-
reported positive arousal. Consistent with the proposed
link between reward processing and placebo responses,
we observed that increases in positive affect ratings dur-
ing placebo administration were related to both greater
placebo-induced NAC DA release and NAC synaptic ac-
tivity during monetary reward anticipation.
We demonstrate that NACDAD2/D3 receptormediated
neurotransmission is activated during the receipt of a pla-
cebo in the context of the anticipation of a painful chal-
lenge in a manner proportional to the anticipated benefit
of the placebo and variations from those predictions. Pla-
cebo-associated DA activation in the dorsal caudate and
putamen have been shown in Parkinson’s disease and
related to improvement of motor function (de la Fuente-
Fernandez et al., 2001). In subsequent analyses of the
same trial, these authors also showed NAC DA activation
that was related to the individual expectation of functional
recovery, but not motor function (de la Fuente-Fernandez
et al., 2002), in a manner similar to what is shown here for
expectation of analgesia. The present work therefore gen-
eralizes ventral basal ganglia DA neurotransmission as an
underlying mechanism across various forms of placebo-
associated expectations. This assertion is consistent
with the increases in metabolism observed in the ventral
basal ganglia when healthy subjects expected a psychos-
timulant drug (methylphenidate) but instead received
a placebo (Volkow et al., 2006). However, and unlike the
previous studies, we also describe that placebo-induced
activation of NAC DA during pain expectation predicted
placebo-induced analgesic effects in subsequent pain tri-
als. These findings are consistent with the hypothesis that
this system is involved in the encoding of the ‘‘incentive
value’’ of the placebo, possibly acting as a gate or permis-
sive system for the formation of placebo effects. Placebo
analgesic effects have been additionally linked to the acti-
vation of endogenous opioid neurotransmission, as evi-
denced by its abolition by the opioid receptor antagonist
naloxone (Amanzio and Benedetti, 1999; Levine et al.,
1978) or directly through themeasurement of endogenous
opioid activity with PET (Zubieta et al., 2005). A colocaliza-
tion of DA D2 receptors with enkephalinergic neurons has332 Neuron 55, 325–336, July 19, 2007 ª2007 Elsevier Inc.been described in the NAC (Badiani et al., 1999; Chen
et al., 1993), which may underlie the involvement of both
DA and opioid mechanisms in placebo analgesia.
The information presented here links variations in the
function of reward processing and saliency response sys-
tems (mesolimbic dopamine, nucleus accumbens synap-
tic responses) with variations in placebo effects in healthy
volunteers. Substantial differences in the magnitude of
placebo effects have been described between disease
processes, or even between individuals within a disease
category (Benedetti et al., 2005, 2006; Huppert et al.,
2004; Keck et al., 2000). The present results indicate
that intrinsic differences in the function of neurobiological
mechanisms involved in reward anticipation processing,
such as the mesolimbic dopaminergic pathway, explain
a substantial proportion of the variance in placebo effects.
The placebo effect then emerges as a resiliency mecha-
nism with broad implications that, given its activation of
specific circuits and mechanisms, can be both examined
and modulated for therapeutic purposes. It also repre-
sents an experimental probe that, beyond its confounding
properties in the study of potentially therapeutic agents,
would help determine dysfunctions in cerebral mecha-
nisms that may impair recovery across a number of condi-
tions.
EXPERIMENTAL PROCEDURES
Subjects
Volunteers were 30 healthy, medication free, right handedmen (n = 23)
and women (n = 7) 24 ± 3 years of age. Fourteen subjects participated
in [11C]raclopride PET, fMRI, pain expectation, and pain challenge
studies. Sixteen additional subjects underwent identical procedures
except that they did not participate in [11C]raclopride PET studies.
A separate sample of 18 healthy males, 20–30 years of age, was
studied twice with the same experimental challenges, except that
they not receive placebo and were not scanned. This group was uti-
lized to rule out systematic effects of study order in the results.
Subjects had no personal history ofmedical, psychiatric illness, sub-
stance abuse or dependence, and no family history of inheritable ill-
nesses. Volunteers were not taking psychotropic medications or hor-
mone treatments, were nonsmokers, and did not exercise in excess
of 1 hr three times a week. Females had regular menstrual cycles
and were studied in the follicular phase of the menstrual cycle (days
4–10 after the onset of menses). Menstrual cycle phase was ascer-
tained with estradiol and progesterone (<3 ng/ml) plasma levels imme-
diately prior to scanning. Written informed consent was obtained in all
cases. All the procedures employed were approved by the University
of Michigan Investigational Review Board for Human Subject Use
and the Radiation Drug Research Committee.
Experimental Sequence
The sequence of experimental events is summarized in Figure 1A. Us-
ing the time of tracer administration as time 0min (T0) for the PET stud-
ies, a pain anticipation condition (pain is expected and rated, but not
received) started at T5 and continued for 20 min (until T25). The antic-
ipation challenges were followed by actual pain challenges starting at
T45, lasting for 20 min (until T65). Subjects remained in the scanner
during this period of time until T90. In placebo studies, placebo admin-
istrations started at T3 and were repeated every 4 min, until T23. In the
case of the pain challenges, placebo administrations started at T43,
were again repeated every 4 min, and were completed at T63. Rating
scales were completed before T0 (baselines) and at T35.
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ter the PET studies in randomized, counterbalanced order, and were
separated from them by 24 to 72 hr, depending on scanner availability
and the scheduling needs of the subjects. Subjects were not informed
of any connection between fMRI and PET studies, and the experiments
were framed in the context of the study of individual variations in the
response to various stimuli.
Pain Expectation Condition, Pain Challenges,
and Placebo Administration
Subjects were placed in the scanner gantry as described under PET
Acquisition, below. Needles (25 1/2-gauge) were placed in both mas-
seter muscles 20 min prior to radiotracer (T20) administration. During
the pain expectation condition and starting 5 min posttracer adminis-
tration (T5), nonpainful sterile isotonic saline (0.9%) was introduced at
a rate of 75 ml/min in the right masseter muscle via a closed infusion
system over 20 min (until T25). Subjects were asked to rate pain inten-
sity every 15 s using an electronic 0–100 visual analog scale (VAS)
placed in front of the scanner gantry. Pain ratingswere invariably 0 dur-
ing this condition. Subjects were informed that the lower end on the
scale denotes ‘‘no pain’’ while the upper bound represents the
‘‘most pain imaginable.’’ However, subjects were instructed to expect
pain of moderate intensity (40 VAS units in the 0–100 scale) during the
trial. The trials were followed by actual 20 min pain challenges on the
left masseter muscle (Stohler and Kowalski, 1999; Zhang et al.,
1993). These challenges started 45 min after tracer administration
(T45 to T65), and consisted of the use 5% hypertonic saline solution
to elicit a pain signal. Since pain sensitivity is highly variable between
individuals, pain was maintained at similar levels of intensity across
subjects over time by the use of an adaptive system that utilizes feed-
back from the subjects. A standard 0.15 ml bolus of 5% NaCl was in-
troduced over 15 s as the initial impulsive input, while recording the
subjects pain intensity response every 15 s. A suitable infusion rate
was then estimated using a computer controller that compares the
subject’s pain rating to the mean rating of 65 subjects in the same de-
cade of age exposed to the same bolus. Subsequently, the adaptive
controller depends entirely on feedback from subjects. The subject
ratings of pain intensity every 15 s. were fed back to the computer
via an analog-digital board, and the infusion rate modulated over
time to maintain a target pain rating between 30 and 40 VAS intensity
units (Stohler and Kowalski, 1999; Zubieta et al., 2001, 2002; Smith
et al., 2006). For the studies including placebo administration, the
same individual infusion profiles generated during the pain challenges
were employed for the placebo studies. High and low placebo
responding during the pain trials was defined using the median
values of their average pain ratings over the 20 min of the challenge
as threshold.
Subjects were given clinical trial-type instructions prior to adminis-
tration of the placebo, so that the conditions of the study would be sim-
ilar to those encountered in typical placebo-controlled drug trials: ‘‘We
are studying the effect of a novel medication with analgesic properties.
This medication is thought to have analgesic effects through the acti-
vation of brain systems that suppress pain.’’ In the written consent
form, it was further explained that they could receive an active drug,
or a substance with no intrinsic pain relief properties.
The placebo condition consisted of the introduction of 1 ml 0.9%
isotonic saline into one of the intravenous ports over 15 s, every 4
min, over 20 min, starting 3 min after radiotracer administration (T3–
T23 for pain anticipation) and T43–T63 for pain trials. Subjects were
informed that the study drug was to be administered by means of
a warning that was followed by a second-by-second count of the infu-
sion timing (15 s) using a computer-generated human voice recording.
Subjects were also asked to estimate the expected analgesia prior to
the introduction of the placebo. After the pain challenges, they were
also asked to estimate the analgesic efficacy of the placebo using
a VAS scale from 0 (no analgesic effect) to 100 (maximum analgesia).Upon completion of the pain expectation trials (T35), the subjective
experience was additionally evaluated using the Positive and Negative
Affectivity Scale (PANAS) (Watson et al., 1988).
PET and MRI Acquisition
Two PET scans were acquired with a Siemens (Knoxville, TN) HR+
scanner in 3-D mode (reconstructed full-width half maximum
FWHM-resolution 5.5 mm in-plane and 5.0 mm axially), with septa
retracted and scatter correction. Participants were positioned in the
PET scanner gantry, and two intravenous (antecubital) lines were
placed. A light forehead restraint was used to eliminate intrascan
head movement. Subjects remained in the scanner for all procedures
(90min total). Image data was analyzed from 5 to 40min posttracer ad-
ministration (pain anticipation condition with and without placebo).
[11C]raclopride was synthesized at high specific activity (>2000
Ci/mmol) by the reaction of O-desmethyl raclopride with 11C-methyl
triflate. Ten to 15 mCi were administered in each of the two scans,
with a mass of raclopride injected of 0.20 ± 0.15 mg/kg per scan. Fifty
percent of the radiotracer dose was administered as a bolus, and the
remaining 50% by continuous infusion for the remainder of the study.
Images were reconstructed using iterative algorithms (brain mode;
Fourier rebinning with ordered subsets-expectation maximization, 4 it-
erations, 16 subsets; no smoothing) into a 128 3 128 pixel matrix in
a 28.8 cmdiameter field of view. Attenuation correctionwas performed
through a 6 min transmission scan (68Ge source) obtained prior to the
PET study, also with iterative reconstruction of the blank/transmission
data followed by segmentation of the attenuation image. Small head
motions during emission scans were corrected by an automated com-
puter algorithm for each subject before analysis, and the images cor-
egistered to each other with the same software (Minoshima et al.,
1993). Time points were then decay-corrected during reconstruction
of the PET data.
Image data were then transformed on a voxel-by-voxel basis into
two sets of parametric maps: (A) a tracer transport measure (K1 ratio)
and (B) a receptor-related measure (Distribution Volume Ratio, DVR)
during pain anticipation trials, using data from 5 to 40 min posttracer
administration. To avoid the need for arterial blood sampling, these
measures were calculated using a modified Logan graphical analysis
(Logan et al., 1996) using the cerebellum (an area devoid of dopamine
D2 receptors). With the partial bolus-continuous infusion radiotracer
administration protocol used, the Logan plot becomes linear by 4 to
5 min after the start of radiotracer administration, allowing the calcula-
tion of receptor measures early after tracer administration. The slope of
the Logan plot is equal to the (f2Bmax/Kd) + 1 for this receptor site
(receptor concentration divided by its affinity for the radiotracer) and
it has been referred to as the Distribution Volume Ratio, (DVR);
f2Bmax/Kd (or DVR - 1) is the ‘‘receptor related’’ measure (also termed
binding potential, BP) (Mintun et al., 1984) or receptor availability
in vivo. The term f2 refers to the concentration of free radiotracer in
the extracellular fluid and is considered to represent a constant and
very small value.
Anatomical MRI scans were acquired on a 3 Tesla scanner (General
Electric, Milwaukee, WI). Acquisition sequences were axial SPGR In-
verse Recovery-Prepared MR (echo time [TE] = 3.4 ms, repetition
time [TR] = 10.5 ms, inversion time [TI] = 200 ms, flip angle = 25, num-
ber of excitations [NEX] = 1, using 124 contiguous images, 1.5 mm
thickness). K1 and DVR images for each experimental period and
MR images were coregistered to each other and to the International
Consortium for Brain Mapping (ICBM) stereotactic atlas orientation.
Statistical parametric maps of differences between conditions (pain
versus baseline) were generated by anatomically standardizing the
T1-SPGR MRI of each subject to the ICBM stereotactic atlas coordi-
nates, with subsequent application of this transformation to the DA
D2/D3 and m-opioid receptor binding maps. The accuracy of coregis-
tration and nonlinear warping algorithms was confirmed for each sub-
ject individually by comparing the transformed MRI and PET images to
each other and the ICBM atlas template.Neuron 55, 325–336, July 19, 2007 ª2007 Elsevier Inc. 333
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gle-shot combined spiral in/out acquisition (Glover and Law, 2001),
gradient echo, TR = 2000 ms, TE = 30 ms, FA = 90, FOV = 20 cm,
64 3 64 matrix. The first five volumes in each session were discarded
to allow for T1 equilibration effects. Functional image preprocessing
included correction for slice-acquisition timing to the middle slice,
realignment to the first volume of each run to correct for intrascan
movement, and smoothing with a Gaussian kernel of 8 mm FWHM
to compensate for small residual anatomic variations across subjects.
Smoothed images were then band pass-filtered with a 128 s high pass
filter to eliminate low frequency signals. A general linear model was
constructed in SPM2 (Welcome Department of Cognitive Neurology,
University College, London, UK) with parameters corresponding to
the type of monetary reward anticipated, modeling each session sep-
arately. Each stimulus type was convolved with the SPM2 canonical
hemodynamic response function.
Monetary Incentive Delay Task
Thirty subjects completed the Monetary Incentive Delay (MID) task in
the fMRI scanner (Knutson et al., 2000). A schematic of the paradigm
is presented in Figure 2. Each MID session consisted of 72 6 s trials:
a trial consisted of a cue, followed by a variable delay interval, followed
by a button-press response to a target. Subjects were then informed of
their success on the preceding trial, as well as their monetary gain or
loss. The cue could be one of seven types, representing three different
levels of monetary gain ($0.20, $1.00, and $5.00), a null condition ($0),
or three levels of monetary loss ($0.20,$1.00, and$5.00). In mon-
etary gain trials, subjects would win the cued amount of money if they
successfully responded during the target presentation. In monetary
loss trials, subjects had to successfully respond to the target to avoid
losing the cued monetary amount. In the null trials, subjects experi-
enced no monetary gain or loss but were still instructed to respond
to the target. During a practice session prior to scanning, each sub-
ject’s reaction timewas used to define the presentation time for the tar-
get where their success rate in the task would be at least 66%.
Data Analysis
Volumes-of-interest (VOI) in the NAC were first drawn in the ICBM ste-
reotactic atlas orientation template using published boundary guide-
lines (Martinez et al., 2003) and then transferred to the PET BP
maps. No global normalization was applied to the PET data, and there-
fore the calculations presented are based on absolute BP (f2 Bmax /
Kd) estimates.
The fMRI time series were analyzed using SPM2 and Matlab soft-
ware. Parameter estimates of event-related activity were established
for each voxel, and contrast images were calculated by applying ap-
propriate linear contrasts to the parameter estimates of each event
type to produce statistical parametric maps. Themain effect of interest
was anticipation of large ($5.00) reward versus null ($0.00) reward. The
resulting statistical image for each subject was then spatially normal-
ized into ICBM space by applying the T1-SPGR transformation param-
eters to the SPM2 contrast image. NAC VOIs were then applied to the
normalized contrast images (Figure 3A). BOLD activations were ex-
tracted from fMRI data to calculate percent change for each event.
These extractions were performed using theMarsbar region of interest
toolbox for SPM (version 0.38). Raw BOLD intensity data was then ex-
tracted from each ROI for each subject and used to determine percent
change, whichwas calculated as the average local BOLD intensity dur-
ing large reward anticipation divided by the average local BOLD inten-
sity during null anticipation, multiplied by 100.
Differences in psychophysical measures, BP and BOLD signal in the
NAC were tested with one-tail paired t tests, at p < 0.05 for within sub-
ject conditions (effects of placebo) because of the expected direction-
ality of the results. One-tail unpaired t tests were utilized for between
subject analyses (high versus low placebo responders) at p < 0.05.
Correlations between variables were tested with Pearson correlations334 Neuron 55, 325–336, July 19, 2007 ª2007 Elsevier Inc.at p < 0.05. Other comparisons are described in the text. Data in the
text is expressed as the mean ± 1 SD.
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